CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Scrip - April 25, 2025

Execs On The Move: 7-11 April 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - April 24, 2025

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation
Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.
Medtech Insight - April 24, 2025

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’
The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.
Medtech Insight - April 24, 2025

Ireland’s Medtech Keeps Calm While Trump Covets Its Healthcare Industry
The Republic of Ireland’s record in life sciences is impressive. Decades of investment, education and training have been major winners for the country’s successful economy. But its success is drawing unwanted attention from the US. Trump wants “to have that.”
Medtech Insight - April 24, 2025

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually
The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.
HBW Insight - April 25, 2025

Governor Newsom Expands Discounted Naloxone Availability To All Californians
After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.
Generics Bulletin - April 24, 2025

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks
The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.
Generics Bulletin - April 24, 2025

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance
Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.
Generics Bulletin - April 24, 2025

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
In Vivo - April 23, 2025

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
In Vivo - April 23, 2025

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
In Vivo - April 23, 2025

Oncology’s Most Eligible Unpartnered Assets
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
In Vivo - April 23, 2025